Maynard Um
-
-
-
-
-
-
-
Keros Therapeutics presents KER-065 trial data at bone research meeting
-
-
-
-
-
-
-
ADAR1 Issues Statement on Keros Therapeutics (KROS) 2025 Director Election Results and Insufficient Capital Return Proposal
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Tops Q1 EPS by 481c
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Tops Q4 EPS by 22c
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Announces Additional Update on the Phase 2 TROPOS Trial
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Announces Update on the Phase 2 TROPOS Trial
-
-
-
-
-
-
-
Cantor Fitzgerald Starts Keros Therapeutics (KROS) at Overweight
-
397,232 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

